In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $10.59 in the prior trading day, Iovance Biotherapeutics Inc (NASDAQ: IOVA) closed at $10.65, up 0.61%. In other words, the price has increased by $0.61 from its previous closing price. On the day, 8.56 million shares were traded. IOVA stock price reached its highest trading level at $10.86 during the session, while it also had its lowest trading level at $10.05.
Ratios:
Our goal is to gain a better understanding of IOVA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.90 and its Current Ratio is at 4.22. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 24, 2024, initiated with a Buy rating and assigned the stock a target price of $17.
On July 29, 2024, Piper Sandler Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $19 to $10.
On November 20, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $12.Goldman initiated its Buy rating on November 20, 2023, with a $12 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 20 ’24 when MCPEAK MERRILL A bought 250,000 shares for $9.15 per share. The transaction valued at 2,287,500 led to the insider holds 320,150 shares of the business.
Dukes Iain D. bought 32,000 shares of IOVA for $292,800 on Feb 20 ’24. The Director now owns 54,000 shares after completing the transaction at $9.15 per share. On Feb 20 ’24, another insider, Rothbaum Wayne P., who serves as the Director of the company, bought 5,000,000 shares for $9.15 each. As a result, the insider paid 45,750,000 and bolstered with 28,067,333 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 3245917440 and an Enterprise Value of 2927370496. For the stock, the TTM Price-to-Sale (P/S) ratio is 30.79 while its Price-to-Book (P/B) ratio in mrq is 4.19. Its current Enterprise Value per Revenue stands at 32.219 whereas that against EBITDA is -7.169.
Stock Price History:
Over the past 52 weeks, IOVA has reached a high of $18.33, while it has fallen to a 52-week low of $3.76. The 50-Day Moving Average of the stock is 4.71%, while the 200-Day Moving Average is calculated to be -1.03%.
Shares Statistics:
The stock has traded on average 6.12M shares per day over the past 3-months and 7991910 shares per day over the last 10 days, according to various share statistics. A total of 256.14M shares are outstanding, with a floating share count of 248.15M. Insiders hold about 18.58% of the company’s shares, while institutions hold 67.93% stake in the company. Shares short for IOVA as of 1728950400 were 60338267 with a Short Ratio of 9.87, compared to 1726185600 on 60293439. Therefore, it implies a Short% of Shares Outstanding of 60338267 and a Short% of Float of 21.98.
